




RealRate

PHARMACEUTICAL 2020

VYNE Therapeutics Inc. Rank 159 of 358





RealRate

PHARMACEUTICAL 2020

VYNE Therapeutics Inc. Rank 159 of 358



The relative strengths and weaknesses of VYNE Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of VYNE Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 102% points. The greatest weakness of VYNE Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 80% points.

The company's Economic Capital Ratio, given in the ranking table, is 98%, being 62% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	78,327
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,661
Liabilities, Non-Current	0
Other Assets	744
Other Compr. Net Income	120
Other Expenses	0
Other Liabilities	0
Other Net Income	2,539
Other Revenues	0
Property and Equipment	98
Research and Development	53,761
Selling, General and Administrative Expense	22,481

Output Variable	Value in 1000 USD
Assets	79,169
Liabilities	10,661
Expenses	76,242
Revenues	0
Stockholders Equity	68,508
Net Income	-73,703
Comprehensive Net Income	-73,643
Economic Capital Ratio	98%